arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Kiniksa Pharmaceuticals International, plc

KNSA

$76.03 ▼ -0.45 (-0.59%) at close

10 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Neutral

auto_awesome

Analytical Summary

Kiniksa Pharmaceuticals International, plc shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $5.6B

Dividend Yield —

Revenue Growth 60.1% ↗

Op. Margin 11.4% ↗

ROIC 9.0% ↗

FCF / Share $1.84 ↗

Trailing P/E 95.0x

Price / Book 9.9x

FCF Yield 2.4%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$677.56M

↑ +60.1% —

Net Income Profit after all expenses

$59.01M

↑ +236.6% —

Operating Margin Operating profit as % of sales

11.4%

↑ +205.7% 60th

FCF / Share Free cash flow per share

$1.84

↑ +416.7% —

Health Breakdown

Profitability

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	60.1% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+651%)	56.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+608%)	22.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+184%)	471.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5791%)	—	—	—	—	—	—
EPS Growth YoY (%)	N/M	N/M	-92.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	11.9% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	N/M	N/M	-92.3% Weak ↓ Weak Declining Year-over-year change in net income	N/M	2.1% Caution ↑ Caution Improving Year-over-year change in net income	0.3% Caution ↑ Caution Improving Year-over-year change in net income	-56.8% Weak Weak Year-over-year change in net income	-59.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	416.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	89.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	128.8% Excellent Excellent Year-over-year change in free cash flow	N/M	16.5% Good Good Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	45.5% Excellent Excellent Compound annual revenue growth over 3 years	122.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—
EPS CAGR 3Y (%)	-32.8% Weak Weak Compound annual EPS growth over 3 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	11.4% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-24%)	-10.8% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-172%)	-9.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-162%)	4.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-70%)	-406.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2809%)	—	—	—	—	—
Effective Tax Rate (%) (%)	33.6% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-19.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	184.6% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1563.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	8.7% Caution ↓ Caution Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-27%)	-10.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-185%)	5.2% Caution ↑ Caution Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-57%)	83.3% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+594%)	-409.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3514%)	—	—	—	—	—
FCF Margin (%) (%)	20.1% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	6.0% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	4.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	2.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-328.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	2.31x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.03x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	9.0% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	4.9% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	41.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-85.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-52.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-74.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	72.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	10.1% Good ↑ Good Improving Operating profit relative to total assets Optimal: > 10%	-7.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	2.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-66.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-137.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	10.4% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-31%)	-9.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	3.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-79%)	46.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+209%)	-85.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-669%)	-51.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-445%)	-71.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-579%)	-37.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-346%)	72.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+382%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Net Debt (USD)	$-165.60M	$-183.58M	$-107.95M	$-122.72M	$-122.47M	$-114.04M	$-46.93M	$-71.98M	$-45.55M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$9.13	$5.93	$3.86	$3.17	$0.56	—	—	—	—	—
Basic EPS, GAAP (USD)	$0.80	$-0.60	$0.20	$2.64	$-2.30	$-2.61	—	—	—	—
Free Cash Flow per Share (USD)	$1.84	$0.36	$0.19	$0.08	$-1.85	$-2.21	—	—	—	—
Book Value per Share (USD)	$7.65	$6.14	$6.26	$5.71	$2.70	$5.04	—	—	—	—
Tangible Book Value per Share (USD)	$7.65	$6.14	$6.26	$5.71	$2.70	$5.04	—	—	—	—
Basic Weighted Avg Shares (shares)	74.20M	71.42M	70.06M	69.38M	68.58M	61.84M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$387.99M	$231.18M	$212.63M	$195.99M	$151.62M	$301.40M	$213.80M	$271.20M	$29.67M	—
Total Equity (USD)	$567.61M	$438.44M	$438.84M	$396.15M	$185.04M	$311.94M	$225.42M	$279.27M	$-89.71M	$-25.73M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$677.56M	$423.24M	$270.26M	$220.18M	$38.54M	—	—	—	—	—
Depreciation Expense (USD)	$196.00K	$448.00K	$1.11M	$1.18M	$1.46M	$2.40M	$2.07M	$286.00K	$28.00K	—
Net Income, GAAP (USD)	$59.01M	$-43.19M	$14.08M	$183.36M	$-157.92M	$-161.38M	$-161.87M	$-103.23M	$-64.87M	—
Operating Cash Flow (USD)	$137.99M	$25.69M	$13.30M	$5.81M	$-126.30M	$-136.53M	$-158.37M	$-81.01M	$-50.22M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 37 quarters

Kiniksa Pharmaceuticals International, plc

Analytical Summary

10-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare KNSA with peers